On April 5, 2023, Bloomberg.com described that Keros Therapeutics, Inc. (NASDAQ:KROS) acquired an common score of “Buy” from the 6 ratings corporations that protect the firm. The optimistic sentiment is attributed to the five financial commitment analysts who have provided a acquire advice for the inventory. Keros Therapeutics, Inc. is […]